This workshop will explore the pending changes in Clozapine REMS, providing psychiatric pharmacists with essential knowledge on the appropriate use of clozapine and the critical role of the therapeutic drug monitoring (TDM) in optimizing patient outcomes. Participatns will gain practical insights into navigating regulatory updates and enhancing clinical decision-making.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Faculty Information
View biographical information
Megan Ehret, PharmD, MS, BCPP, FAAPP
Professor
Co-Director of Mental Health Program
Vice-Chair of Academic Affairs
Department of Practice, Sciences, and Health Outcomes Research
University of Maryland School of Pharmacy
Deanna L. Kelly, PharmD, BCPP
Dr. William and Carol Carpenter Professor in Psychiatry for Mental Illness Research
Acting Director, Maryland Psychiatric Research Center
Chief, Treatment Research Program (TRP)
University of Maryland School of Medicine
Robert O. Cotes, MD, DFAPA
Professor and Distinguished Physician
Co-Director, Clinical and Research Program for Psychiatric and Behavioral Sciences
Emory University School of Medicine
Editor-in-Chief, Community Mental Health Journal
Learning Objectives
- Explain the pending changes in the Clozapine REMS program and their implications of psychiatric pharmacy practice.
- Identify clinical scenarios where clozapine is the preferred treatment and describe its unique role in managing treatment-resistant schizophrenia and reducing suicidal behavior in patients with schizophrenia.
- Discuss the importance of TDM in clozapine therapy, its rapid results, and how to interpret levels and adjust dosages to optimize efficacy and safety.
- Develop strategies to integrate updated REMS requirements and TDM protocols into pharmacy workflows to ensure compliance and improve patient care.
- Evaluate case studies to illustrate how the use of clozapine, informed by TDM, leads to better therapeutic outocmes for patients with complex psychiatric needs.
Continuing Education Credit and Disclosures
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.